scorecardresearch
Follow Us:
Tuesday, June 28, 2022

Bharat Biotech to pay compensation if Covaxin causes side effects

According to an industry expert, the company is liable to pay compensation to people in case of serious side effects as the vaccine is being administered while in the clinical trial mode.PTI

By: PTI | Hyderabad |
Updated: January 16, 2021 3:23:51 pm
Covid vaccine, MaharashtraBharat Biotech on Saturday announced the prices of Covaxin. (Express photograph by Arul Horizon)

Bharat Biotech, which has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, said the company will pay compensation to recipients in case of any serious adverse effects experienced after receiving the antidote.

In the consent form to be signed by the vaccine recipients, Bharat Biotech said, “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres/hospitals.” Follow Covid-19 Live Updates here

“The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine,” the consent form said. In phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19. However the clinical efficacy of the vaccine is yet to be established and it is still being studied in phase 3 clinical trials, the vaccine maker said.

“Hence it is important to appreciate that receiving the vaccine does not mean that other precautions related to COVID-19 need not be followed,” the consent form said.

Best of Express Premium
Rationalisation, reforms may test Centre-state relations at GST meetPremium
Clampdown and unclear policy prompt crypto exchange founders to leave IndiaPremium
Explained: What is the 2/3rds rule in anti-defection law?Premium
UPSC Key-June 27, 2022: Know the relevance of ‘Deputy Speaker’ to ‘Nation...Premium

According to an industry expert, the company is liable to pay compensation to people in case of serious side effects as the vaccine is being administered while in the clinical trial mode.

The central licensing authority has granted permission for the sale or distribution of Covaxin for restricted use in emergency situations in public interest as an abundant caution, in clinical trial mode.

Meanwhile, Joint Managing Directorof BharatBiotech International Ltd, SuchitraElla in her twitter account said, “Covaxin & Bharat Biotech is truly humbled & honoured to be of service to the nation & the fraternity of all first responders of covid who have served public health.”

 

 

Express Subscription Do not hit the wall, subscribe for the best coverage out of India starting at just $5 per month

📣 Join our Telegram channel (The Indian Express) for the latest news and updates

For all the latest India News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement